About the Authors
- Michael R. Breen
-
Affiliation Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America
- Marta Camps
-
Affiliations Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain, IBUB Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
- Francisco Carvalho-Simoes
-
Affiliations Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain, IBUB Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
- Antonio Zorzano
-
Affiliations Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- Paul F. Pilch
-
* E-mail: ppilch@bu.edu
Affiliations Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
Competing Interests
Troglitazone, a gift from Pfizer, Groton, CT, USA, was used in this study. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MRB MC FCS AZ PFP. Performed the experiments: MRB MC FCS AZ. Analyzed the data: MRB MC FCS AZ PFP. Contributed reagents/materials/analysis tools: MC FCS AZ PFP. Wrote the paper: MRB PFP.